Dr. Xiao-Ming (Mindy) Wang and colleagues from the Michigan Center for Translational Pathology and Department of Pathology published a groundbreaking finding from an inter-institutional study regarding TRIM63 in Modern Pathology [...]
Findings offer clues to why some types of renal cell carcinoma respond to immunotherapy while others do not — it’s a scientific riddle tangled up in a complex web. How do you turn an immune cold cancer into one that responds to immunotherapy?
Not all kidney cancers behave the same, with wildly different responses to immunotherapy or other treatments – and wildly different outcomes for patients as a result. By sequencing the RNA of individual cells within multiple benign and cancerous kidney tumors, researchers from the University of Michigan Rogel Cancer Center have identified the cells [...]
A research effort by Drs. Jolanta Grembecka and Tomasz Cierpicki was just published in Nature Communications. Learn more about the protein made by the ASH1L gene, which plays a key role in the development of acute leukemia, along with other diseases [...]
MiTF renal cell carcinoma can masquerade as other subtypes and may not respond as well to front-line therapies.
A new study by the University of Michigan's Rogel Cancer Center analyzed patients with cancer and the factors that cause the cancer to spread to the liver, leading to worse outcomes.
Clinical trials underway are testing whether drugs that target the androgen receptor – successful in controlling prostate cancer – could also work against the coronavirus. wo proteins, ACE2 and TMPRSS2, help the coronavirus gain entry and replicate within cells. TMPRSS2 is well-known to Arul Chinnaiyan, MD, PhD. His lab discovered that TMPRSS2 fuses with the ETS gene to drive more than half of all prostate cancers [...]
A new study led by Drs. Jolanta Grembecka and Tomasz Cierpicki of the Department of Pathology was just published in Blood's American Society of Hematology. The research focuses on combinatorial treatment with menin and FLT3 and how inhibitors induce complete remission in acute myeloid leukemia (AML) with activating FLT3 mutations [...]
Congratulations to Dr. Celina Kleer who was awarded the American Society for Investigative Pathology (ASIP)'s 2020 Outstanding Investigator Award. Dr. Kleer receives the award for her demonstrated excellence in research in experimental pathology [...]
Structural biology techniques helped researchers target the nuclear receptor-binding SET domain family, whose malfunction is associated with several types of cancer.
Dr. Celina Kleer named 2019 AACR Outstanding Investigator in Breast Cancer Research
A Phase I clinical trial, using a structurally related analog of the compound, is currently enrolling patients.
The American Association for Cancer Research announced that Celina Kleer, MD, the Harold A. Oberman Collegiate Professor of Pathology and Director of the Breast Pathology Program, will be the recipient of the 2019 Outstanding Investigator in Breast Cancer Research, supported by the Breast Cancer Research Foundation.